Stephen A. Harrison

机构：University of Oxford, Pinnacle Clinical Research · ORCID：0000-0003-2407-2685

发表论文 20 篇 · 总被引 2305 次 · h-index 6

代表论文

• A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis (2024 · New England Journal of Medicine · 被引 1963)
• Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis (2024 · Clinical Gastroenterology and Hepatology · 被引 160)
• Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of pre-cirrhotic fibrosis due to non-alcoholic steatohepatitis (2023 · Journal of Hepatology · 被引 128)
• A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH (2025 · Journal of Hepatology · 被引 23)
• ALADDIN: A Machine Learning Approach to Enhance the Prediction of Significant Fibrosis or Higher in Metabolic Dysfunction-Associated Steatotic Liver Disease (2025 · The American Journal of Gastroenterology · 被引 16)
• LBO-002 Efruxifermin significantly reduced liver fibrosis in MASH patients with F2-F3 fibrosis, with sustained improvement in liver injury and resolution of steatohepatitis over 96 weeks (HARMONY phase 2b study) (2024 · Journal of Hepatology · 被引 8)